Nixon Jane, Smith Isabelle L, Brown Sarah, McGinnis Elizabeth, Vargas-Palacios Armando, Nelson E Andrea, Coleman Susanne, Collier Howard, Fernandez Catherine, Gilberts Rachael, Henderson Valerie, Muir Delia, Stubbs Nikki, Walker Kay, Wilson Lyn, Hulme Claire
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9JT, UK.
Leeds Teaching Hospitals NHS Trust, Leeds, UK.
EClinicalMedicine. 2019 Sep 3;14:42-52. doi: 10.1016/j.eclinm.2019.07.018. eCollection 2019 Sep.
Pressure ulcers (PUs) are complications of serious acute/chronic illness. Specialist mattresses used for prevention lack high quality effectiveness evidence. We aimed to compare clinical and cost effectiveness of 2 mattress types.
Multicentre, Phase III, open, prospective, parallel group, randomised controlled trial in 42 UK secondary/community in-patient facilities.2029 high risk (acutely ill, bedfast/chairfast and/or Category 1 PU/pain at PU site) adult in-patients were randomised (1:1, allocation concealment, minimisation with random element) factors including: centre, PU status, facility and consent type. Interventions were alternating pressure mattresses (APMs) or high specification foam (HSF) for maximum treatment phase 60 days. Primary outcome was time to development of new PU Category ≥ 2 from randomisation to 30 day post-treatment follow-up in intention-to treat population. Trial registration: ISRCTN 01151335.
Between August 2013 and November 2016, we randomised 2029 patients (1016 APMs: 1013 HSF) who developed 160(7.9%) PUs. There was insufficient evidence of a difference between groups for time to new PU Category ≥ 2 Fine and Gray Model Hazard Ratio HR = 0.76, 95%CI0.56-1.04); exact P = 0.0890; absolute difference 2%). There was a statistically significant difference in the , Fine and Gray model HR = 0.66, 95%CI, 0.46-0.93; exact P = 0.0176); 2.6% absolute difference). Economic analyses indicate that APM are cost-effective.There were no safety concerns.
In high risk (acutely ill, bedfast/chairfast/Category 1 PU/ pain on a PU site) in-patients, we found insufficient evidence of a difference in time to PU development at 30-day final follow-up, which may be related to a low event rate affecting trial power. APMs conferred a small treatment phase benefit. Patient preference, low PU incidence and small group differences suggests the need for improved targeting of APMs with decision making informed by patient preference/comfort/rehabilitation needs and the presence of potentially modifiable risk factors such as being completely immobile, nutritional deficits, lacking capacity and/or altered skin/Category1 PU.
压疮是严重急性/慢性疾病的并发症。用于预防的专科床垫缺乏高质量的有效性证据。我们旨在比较两种床垫类型的临床效果和成本效益。
在英国42家二级/社区住院设施中进行多中心、III期、开放、前瞻性、平行组随机对照试验。2029名高危(急性病、卧床/坐椅受限和/或1期压疮/压疮部位疼痛)成年住院患者被随机分组(1:1,分配隐藏,随机因素最小化),因素包括:中心、压疮状态、设施和同意类型。干预措施为交替压力床垫(APM)或高规格泡沫床垫(HSF),最长治疗期为60天。主要结局是在意向性治疗人群中,从随机分组到治疗后30天随访期间出现新的≥2期压疮的时间。试验注册号:ISRCTN 01151335。
2013年8月至2016年11月期间,我们将2029名患者随机分组(1016名使用APM,1013名使用HSF),其中160名(7.9%)发生了压疮。在出现新的≥2期压疮的时间方面,两组之间没有足够的证据表明存在差异(精细和灰色模型风险比HR = 0.76,95%CI 0.56 - 1.04);确切P = 0.0890;绝对差异2%)。在[具体方面]存在统计学显著差异(精细和灰色模型HR = 0.66,95%CI 0.46 - 0.93;确切P = 0.0176);绝对差异2.6%)。经济分析表明APM具有成本效益。没有安全问题。
在高危(急性病、卧床/坐椅受限/1期压疮/压疮部位疼痛)住院患者中,我们发现在30天最终随访时,出现压疮的时间差异没有足够证据,这可能与低事件发生率影响试验效能有关。APM在治疗期有小的益处。患者偏好、低压疮发生率和小组差异表明,需要根据患者偏好/舒适度/康复需求以及存在潜在可改变的风险因素(如完全不能活动、营养缺乏、无行为能力和/或皮肤改变/1期压疮)来改进APM的靶向使用,并为决策提供信息。